30results about How to "Efficient and specific killing" patented technology

The invention provides a method for preparing TCR knockout T cell receptor gene-modified T cells targeting NY-ESO-1, which comprises the following steps: by knocking out the TCR gene on T lymphocytesand preparing T cell receptors targeting NY-ESO-1, and the TCR knockout T cell receptor gene-modified T cell targeting NY-ESO-1 is obtained. The TCR knockout T cell receptor gene-modified T cell targeting NY-ESO-1 can effectively prevent the mismatch of endogenous and exogenous TCR alpha-chain and beta-chain existing in T cells, autoimmune responses are avoided, and efficient and specific killingperformance of NY-ESO-1 positive tumor cells can be kept. The method also provides an application of the TCR knockout T cell receptor gene-modified T cells targeting NY-ESO-1.

The invention discloses a nano-drug based on a terminal lipoyl-containing star polymer. A side chain lipoyl-containing star polymer is obtained by esterification reaction; LA substitution degree controllability has excellent biocompatibility and can be used for controlling a drug release system; a prepared cancer-targeting reduction sensitive reversible cross-linked polymer nanoparticle nano-drugsupports an in vivo stable long cycle, is enriched in cancer tissues, efficiently enters cells, and quickly decrosslinks in the cells to release the drug; cancer cells are efficiently and specificallykilled, so that toxic or side effects caused by growth of the cancers are effectively inhibited.

The invention discloses a star-shaped polymer containing a lipoyl group at the end, a preparation method thereof, polymer nanoparticles prepared therefrom and applications thereof. The star-shaped polymer containing lipoyl group in the side chain is obtained by esterification. The degree of LA substitution is controllable and has excellent biocompatibility. It can be used to control the drug release system, and the prepared cancer-targeted reduction-sensitive reversible cross-linked polymer Nano-particles and nano-drugs support stable long-term circulation in the body, but are highly enriched in cancer tissues and efficiently enter cells, quickly de-crosslink and release drugs in cells, efficiently and specifically kill cancer cells, and effectively inhibit the growth of cancer without causing toxic side effects.

The present invention provides a chimeric antigen receptor targeting EGFRvIII with high affinity. The chimeric antigen receptor is mutated from a commonly used chimeric antigen receptor targeting EGFRvIII. Its amino acid sequence is as shown in SEQ ID NO:1 shown. The present invention also provides a cord blood nucleated cell containing the chimeric antigen receptor, which can efficiently target the EGFRvIII antigen through the chimeric antigen receptor, has a stronger ability to kill EGFRvIII-positive tumor cells, and can be used to prepare prophylactic and Drugs for the treatment of a variety of EGFRvIII-positive tumors.